Health Care [ 6/12 ] | Biotechnology [ 19/73 ]
NASDAQ | Common Stock
PharvarisN. V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
PharvarisN. V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 25, 25 | 0.00 Increased by +100.00% | -0.77 Increased by +100.00% |
| Apr 7, 25 | -0.64 Decreased by -23.08% | -0.72 Increased by +11.30% |
| Dec 31, 24 | -0.64 Increased by +21.95% | -0.73 Increased by +11.91% |
| Nov 13, 24 | -0.77 Decreased by -32.76% | -0.59 Decreased by -30.05% |
| Aug 5, 24 | -0.60 Increased by +4.76% | -0.58 Decreased by -3.45% |
| May 8, 24 | -0.52 Increased by +55.56% | -0.56 Increased by +7.14% |
| Mar 6, 24 | -0.82 Increased by +34.40% | -0.58 Decreased by -41.38% |
| Nov 2, 23 | -0.58 Decreased by -132.00% | -0.60 Increased by +3.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -46.34 M Decreased by -65.39% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -34.76 M Decreased by -6.15% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -41.71 M Decreased by -76.75% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -29.73 M Decreased by -4.16 K% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -28.02 M Decreased by -23.81% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -32.75 M Increased by +16.45% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -23.60 M Decreased by -178.03% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | 733.08 K Increased by +105.81% | Increased by +N/A% Decreased by N/A% |